PAREXEL EXPERT TO ADDRESS KEY ASPECTS OF CONDUCTING CLINICAL TRIALS IN CHINA AT 7th ANNUAL PARTNERSHIPS IN CLINICAL TRIALS CONGRESS
BOSTON, MA, November 3, 2008 — Albert Liou, Corporate Vice President and General Manager, Asia-Pacific Region, at PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, will present “What Can China Really Deliver in Terms of Cost and Efficiency Savings in Running Clinical Trials?” at the 7th Annual Partnerships in Clinical Trials Congress and Exhibition, to be held November 4 - 7, 2008 at the Estrel Convention Center in Berlin, Germany. PAREXEL is a sponsor of the congress.
During PAREXEL’s presentation, taking place on Wednesday, November 5 at 3:25 p.m. CET, Mr. Liou will explore various issues and considerations for conducting clinical research in China, including approaches to identify well-established investigator sites, the extent of improvements in quality and innovation, strategies for overcoming regulatory hurdles, and ways to ensure compliance with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMEA), and GxP standards.
With 13 locations throughout the Asia-Pacific region, including offices in Beijing, Hong Kong, and Shanghai, China, PAREXEL has had a long-term commitment to providing a high level of standardization and quality clinical development services in these geographies. PAREXEL helps clients address key challenges in conducting studies in the Asia-Pacific region and globally, including accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality.
For over 25 years, PAREXEL has been a proven and committed partner to pharmaceutical, biotechnology, and medical device companies looking to bring innovative new products to market. PAREXEL has extensive experience in providing comprehensive worldwide services to companies of all sizes. With deep expertise and capabilities in consulting, clinical research, eClinical technologies, and medical communications, PAREXEL has helped drive the success of thousands of its clients’ development programs, and has assisted clients in getting their products to patients in need. Attendees at the 7th Annual Partnerships in Clinical Trials Congress and Exhibition 2008 can visit with PAREXEL’s experts at Booth #324 in the exhibit hall to discuss these capabilities.
For more information about PAREXEL’s Clinical Research Services visit: http://www.parexel.com/clinical_research.html
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.